Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
| Autor: | Philippe Moreau, Nizar J. Bahlis, Jesús F. San-Miguel, Kihyun Kim, Kaida Wu, Shinsuke Iida, Gordon Cook, Hervé Avet-Loiseau, Nushmia Z. Khokhar, Ajai Chari, A. Kate Sasser, Andrew Belch, Naoki Takezako, Jonathan L. Kaufman, Lisa O'Rourke, H. Miles Prince, Christopher Chiu, Lotfi Benboubker, Marc Lalancette, Saad Z. Usmani, Jordan M. Schecter, P. Joy Ho, James Morton, Jin Seok Kim, Heather J. Sutherland, Darrell White, Tara Cochrane, Albert Oriol, Tineke Casneuf, Meletios A. Dimopoulos, Hila Magen, David Soong, Merav Leiba |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Neoplasm Residual Kaplan-Meier Estimate Article Plasma Cell Disorders Dexamethasone law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Internal medicine Antineoplastic Combined Chemotherapy Protocols Outcome Assessment Health Care medicine Humans Lenalidomide Aged Aged 80 and over business.industry Hazard ratio Antibodies Monoclonal Daratumumab Hematology Middle Aged Minimal residual disease Confidence interval 3. Good health Clinical trial Drug Resistance Neoplasm 030220 oncology & carcinogenesis Female Neoplasm Recurrence Local Multiple Myeloma business 030215 immunology medicine.drug |
| Zdroj: | Haematologica r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol instname |
| ISSN: | 0390-6078 |
| Popis: | In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly reduced risk of progression/death versus lenalidomide/dexamethasone alone in relapsed/refractory multiple myeloma. We provide one additional year of follow-up and include the effect on minimal residual disease and in clinically relevant subgroups. After 25.4 months of follow-up, daratumumab plus lenalidomide/dexamethasone prolonged progression-free survival versus lenalidomide/dexamethasone alone (median not reached vs 17.5 months; hazard ratio, 0.41; 95% confidence interval, 0.31-0.53; P 12 and =12 months, >6 and =6 months. No new safety signals were observed. In relapsed/refractory multiple myeloma patients, daratumumab plus lenalidomide/dexamethasone continued to improve progression-free survival and deepen responses versus lenalidomide/dexamethasone. TRIAL REGISTRATION: clinicaltrials.gov identifier: NCT02076009. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|